| Code | CSB-RA001670MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Lusvertikimab, targeting the interleukin-7 receptor (IL7R, also known as CD127). IL7R is a type I transmembrane protein that forms part of the heterodimeric receptor for interleukin-7, a cytokine essential for T cell and B cell development, homeostasis, and survival. The receptor plays a critical role in lymphocyte maturation and maintenance of immune memory. Dysregulation of IL7R signaling has been implicated in various autoimmune and inflammatory conditions, including multiple sclerosis, inflammatory bowel disease, and primary immunodeficiencies, making it an important therapeutic target for immune-mediated disorders.
Lusvertikimab is a clinical-stage therapeutic antibody designed to modulate IL7R activity and has been investigated for treatment of autoimmune diseases. This biosimilar antibody provides researchers with a valuable tool for investigating IL7R-mediated signaling pathways, studying lymphocyte biology, and exploring immune system regulation in disease models. It supports mechanistic studies examining the role of IL7R in immune cell development and function, as well as preclinical research into potential therapeutic interventions for immune-related pathologies.
There are currently no reviews for this product.